Abstract OBJECTIVE: Experimental and clinical studies have indicated a beneficial effect of retrograde lung preservation on post-transplant results. Accordingly, we conducted a non-randomized trial.
INTRODUCTION
Since the early 1980s, pulmonary transplantation has developed to a widely available option for patients with end-stage pulmonary diseases potentially offering improved life expectancy and quality of life. Lung transplantation is related to increased incidences of infections, acute or chronic rejections and primary graft dysfunction (PGD) when compared with results of other solid organ transplants. PGD is widely accepted as a fractional consequence of ischaemia-reperfusion (IR) injury that still remains a major contributor to relevant post-transplant morbidity and mortality [1, 2] .
To potentially attenuate the degree of IR injury and, consecutively, PGD, an extensive spectrum of preservation techniques have been evaluated preclinically. Many of those were put into clinical practice, but the ideal strategy to relevantly reduce the incidence of PGD is still elusive. Hypothermic antegrade flush preservation via the main pulmonary artery has been accepted as a standard protocol worldwide. The type of solution remains controversial, but a substantial number of programmes have adopted low-potassium dextran (LPD) solution as a standard [3] .
Two limitations had been attributed to the antegrade flush preservation: pulmonary vasculature constriction and the ignored bronchial circulation [4] [5] [6] . Therefore, preclinical evidence attests to the advantage of retrograde perfusion due to improved anatomical distribution of the preservation solution in the bronchial vasculature and parenchyma, leading to enhanced functional parameters, decreased tendency for post-transplant pulmonary oedema and enhanced surfactant function [6] [7] [8] [9] [10] [11] [12] .
Clinical reports on initial retrograde lung preservation are scarce, but uniformly report on a feasible and safe preservation technique including sufficient cardiac graft function subsequent to simultaneous recovery and adequate early post-transplant lung graft function [4, 13, 14] . Others described a combined antegrade flush prior to organ recovery and secondary retrograde ex situ perfusion resulting in sufficient graft preservation [3, 15, 16] .
To evaluate the results following retrograde compared with antegrade lung preservation, we conducted a clinical analysis of our patients. We hypothesized that retrograde perfusion would result in lower PGD grades and fewer bronchial healing complications.
PATIENTS AND METHODS

Patients
A total of 228 consecutive patients who underwent single (SLTx) or bilateral (BLTx) lung transplantation with LPD preserved grafts at Hannover Medical School were enrolled into this study. Patients on extracorporeal lung support and/or invasive mechanical ventilation prior to lung transplantation were excluded. Donor characteristics and recipient data were recorded. Follow-up data included evidence of bronchial healing alterations, evidence of bronchiolitis obliterans syndrome (BOS) and survival.
Lung graft recovery and transplantation
Acceptance of donor lungs was based on widely established and accepted criteria [17, 18] . Pretreatment of the donor included an intravenous bolus administration of 500 mg of prednisolone. A dose of 40 µg of prostacycline was implemented for graft preservation; since 2001, our own experimental data have revealed beneficial results of prostacycline on post-transplant graft and surfactant function [19] . A volume of 4000 ml of LPD (Perfadex®, Vitrolife, Sweden) pH-balanced by trometamol; tris-hydroxymethyl-aminomethane (THAM) at a temperature 4 and 8°C was employed for flush preservation. No randomization into the two groups was performed. Instead, we evaluated for a retrograde preservation technique prior to lung recovery and discussed it with the cardiac recovery team in charge on site. This method was applied only in the case of consent. In the case of any concern or refusal, the conventional antegrade preservation (AP) technique was used. Retrograde in situ lung perfusion (RP) alone was performed by surgeons trained in this technique (Bernhard Gohrbandt, Gregor Warnecke and Stefan Fischer) as formerly described by our group [15] , whereas AP alone was achieved via the main pulmonary artery. The route of preservation solution delivery was either antegrade or in situ retrograde and was never combined in the study cohort. Mean graft ischaemic times were expressed as mean times ± standard deviation of right and left lung grafts for BLTx or of single grafts for SLTx.
Lung transplantation was mainly carried out via anterolateral thoracotomy. Cardiopulmonary bypass was used dependent on gas exchange, pulmonary artery pressures and cardiac performance when test clamping the pulmonary artery with one-sided lung ventilation or due to other intraoperative factors. Clamshell thoracotomy was sometimes necessary depending on the anatomical situs or in the presence of massive adhesions. Supplementation of nitric oxide at 20 ppm was employed for mechanical ventilation in all patients intraoperatively.
International Society for Heart and Lung Transplantation grading and primary graft dysfunction Oxygenation indices (PaO 2 /FiO 2 , ratio of arterial partial pressure of oxygen to inspired fraction of oxygen) were calculated at 0, 12, 24, 48 and 72 h (T0, T12, T24, T48 and T72) after ICU admission. PGD was graded in adoption of the proposal by the International Society for Heart and Lung Transplantation [20] as follows: Grade III (severe), oxygenation index was <200, regardless of chest X-ray findings; Grade II (serious), oxygenation index ranged between 200 and 300. To discriminate PGD Grade I (mild) from Grade 0, all chest radiographs of these patients obtained at ICU admission and 24, 48 and 72 h thereafter were reviewed by three independent observers who were not acquainted with the route of preservation delivery. Oxygenation index >300 and any degree of parenchymal infiltration in chest X-ray was ranked Grade I, and no infiltration Grade 0. All patients extubated within the initial 72 h posttransplant were considered as Grade I or 0 after extubation depending on chest radiograph findings.
Basic medical treatment
All recipients received 1000 mg of methylprednisolone intraoperatively. The maintenance immunosuppressive regimen was started within 24-48 h after lung transplantation and included cyclosporine, mycophenolate mofetil and corticosteroids. All patients received valganciclovir as cytomegalovirus (CMV) prophylaxis for the initial 3 months after transplantation.
Follow-up
All patients were regularly followed up in our outpatient clinic after hospital discharge. Bronchoscopies, spirometric lung function tests, chest radiographs and laboratory tests were routinely performed at each visit. Bronchoscopic findings regarding the anastomotic region were documented.
Trans-bronchial biopsies for surveillance of graft rejection were not part of our clinical routine protocol.
BOS was diagnosed when FEV 1 repeatedly fell below 80% of the post-transplant best FEV 1 without any other specific explanation.
Neither technique of organ recovery nor of graft implantation had been altered, other than retrograde versus antegrade perfusion of the donor lungs.
Statistical analysis
Data were prospectively recorded followed by a retrospective analysis performed with the Predictive Analytics Software (PASW for Windows, version 20; SPSS, Chicago, IL, USA). All data are expressed as means ± standard deviation. To determine the significance of mean values of recipient or donor characteristics between groups, the t-test was employed. The Pearson χ 2 test was used for comparison of characteristic values between the cohorts. For correlation, a Pearson's Rho test was used. Subsequent to propensity scoring multivariate analysis was performed using Cox regression including the Wald test to assess effects of peri-and postoperative variables on the impact for survival. Hazard ratios including 95% confidence intervals were determined. To calculate the correlation of non-parametric characteristics with each other, the Mann-Whitney U-test was employed. The Kaplan-Meier method including the log-rank test to assess significances was performed for analysis of patient's survival and freedom from BOS. P-values <0.05 were considered significant.
RESULTS
Of the 228 consecutive patients, 19 were excluded from further analysis because of invasive respiratory support before the transplant. The mean follow-up period was 4.3 ± 2.7 (median 5.3) years in the AP and 4.6 ± 3.2 (median 6.2) years in the RP group (mean values P = 0.456; median values P = 0.161). Of 209 lung grafts, 36 (17.2%) were retrogradely preserved. Donor, graft and recipient characteristics are depicted in Table 1 and were grossly comparable between groups. With a tendency to more frequent use of cardiopulmonary bypass for transplantation, the time on bypass was significantly longer in the RP group. There was a significant trend toward prolonged graft ischaemic time in the AP cohort. Fig. 1 . The incidence of severe PGD (Grade 3) in relation to non-severe PGD was comparable between groups at T0 (25.0% AP vs 13.9% RP, P = 0.168), T12 (11.0% AP vs 8.6% RP, P = 0.667), T24 (9.1% AP vs 11.8% RP, P = 0.629) and T48 (6.2% AP vs 3.7% RP, P = 0.618). Frequency of severe PGD was significantly increased in the RP cohort at T72 (2.2% AP vs 14.8% RP, P = 0.016) and correlated with retrograde preservation at this time point (P = 0.003). The pretransplant prevalence of pulmonary hypertension revealed no correlation to the incidence of severe PGD in either group at any time. Similarly, the employment of cardiopulmonary bypass for transplantation showed no correlation to the occurrence of severe PGD at any time point, though at T72 the correlation in the RP group was almost significant (P = 0.066). Correspondingly, for the type of transplantation, SLTx or BLTx, no correlation to the onset of severe PGD was found in the complete cohort within 48 h post-transplant.
Requirement of extracorporeal membrane oxygenation (ECMO) for primary graft failure was significantly higher in the RP cohort (1.2% AP vs 8.3% RP, P = 0.010) after a mean post-transplant period of 1.8 ± 1.9 days. The frequency of reintubation for respiratory insufficiency subsequent to initial post-transplant extubation was significantly increased in the RP group (18.8% AP vs 38.9% RP, P = 0.009). However, the duration of mechanical ventilation prior to the initial extubation was shorter in the RP group [(hours) 127 ± 272 AP vs 69 ± 167, P = 0.098; median 26.5 AP vs 18 RP, P = 0.213]. The 30-day mortality was comparable between groups (8.1% AP vs 11.1% RP, P = 0.557).
Patient survival and follow-up
Survival rates and incidence of BOS within the initial 3 posttransplant years revealed a beneficial trend in the AP group. Furthermore, the incidence of BOS after transplantation indicated a significantly lower rate in the AP group (P = 0.031) as listed in Table 2 .
As depicted in Fig. 2 , Kaplan-Meier analysis of survival ( Fig. 2A ) and BOS-free survival (Fig. 2B ) indicated no significant differences between both groups, but revealed an impaired BOS-free survival in the RP cohort.
Cox regression analysis on survival revealed postanastomotic bronchial graft stenosis and severe PGD 24 h after ICU admission as significant hazard factors. Female recipient gender showed a beneficial effect on survival as illustrated in Table 3 . Interestingly, in Kaplan-Meier subanalysis, retrograde preservation of single lung grafts was followed by the best survival prognosis (P = 0.040), whereas Cox regression for retrograde flush revealed no significant effect in the complete cohort (Table 3 , a and b).
In the AP group, 319 bronchial anastomoses and, in the RP cohort, 67 anastomoses were followed up.
Bronchial dehiscences occurred in 5 patients within 6-8 weeks post-transplant, in 2 patients of the RP group and in 3 patients of the RP cohort. This reflected a significantly higher incidence in the RP cohort (1.2% AP vs 8.3% RP, P = 0.010). Overall, in 3 patients, both bronchial anastomoses were affected and in 2 patients only the right anastomosis, resulting in a dehiscence rate of 0.9% (3 of 319) in AP patients and 7.5% (5 of 67) in the RP cohort. Mean graft ischaemic times were comparable (right lungs P = 0.808, left lungs P = 0.949) in patients with bronchial dehiscences (right lungs 306 ± 119, left lungs 389 ± 135 min) and without dehiscences (right lungs 319 ± 112, left lungs 386 ± 106 min). Three of these 5 patients accounted for post-transplant in-hospital mortality.
In the central bronchial system, we observed development of obstructive airway complications (OACs), both in SLTx recipients and unilateral or bilateral with no prevalence of either side in BLTx Survival in the AP group was non-significantly improved within the initial 3 post-transplant years compared with the RP cohort. BOS was significantly more frequent in the RP cohort 6 months after transplantation (P = 0.036). The incidence of BOS within 3 years after lung transplantation was grossly higher in the RP cohort. Bold values indicate statistically significant of P values <0.05. AP: antegrade lung preservation; RP: retrograde in situ lung perfusion; BOS: bronchiolitis obliterans syndrome. recipients. The occurrence of these stenoses was more frequent in the AP group (24.9% AP vs 13.9% RP, P = 0.218). The underlying mechanism of these OACs remained unclear. Analysis of available donor, graft or recipient characteristics revealed no specific results except a significantly higher incidence in patients following BLTx (P = 0.011), as presented in Table 4 . These OACs mainly developed within the initial 6 months after transplant. None of these patients required surgical treatment or retransplantation in this cohort. The OACs were handled interventionally by positioning of intrabronchial stents, (recurrent) bronchoscopy-guided laser ablation or both.
DISCUSSION
This clinical study does not support potential beneficial early effects of retrograde lung flush preservation alone compared with antegrade perfusion alone, as suggested by preclinical studies previously.
There are several limitations to this study. Being dependent on individual retrieval surgeons among a larger team of retrieval surgeons, randomization was not feasible in our programme. Although data were prospectively recorded, this remains a retrospective analysis. The sizes of the two study cohorts are different (173 vs 36), potentially resulting in an underestimation or overestimation of rare risks, complications or adverse events in the RP cohort. Older recipients and donors, higher incidences of employment and significant longer duration of CPB, more urgent waiting list status and a higher incidence of interstitial lung pathologies, while not significantly different alone, may still have resulted in confounding higher incidences of BOS in the RP group within the initial 3 post-transplant years. A selection of these aspects revealed no significant influence on survival in multivariate analysis (Table 3, a) . It remains elusive why the use and duration of CPB was increased in the RP cohort. Preclinically, functional parameters of the grafts as intrapulmonary shunts, compliance and inflammatory cells in bronchoalveolar lavage fluid were beneficially altered in grafts after combined pulmonary and bronchial arterial flush in comparison with antegrade flush only [6] . Retrograde administration led to increased retrograde flow from the bronchial artery ostia into the descending aorta compared with antegrade lung perfusion and may indicate an improved perfusion of the bronchial arteries [4] . There is evidence that retrograde perfusion may result in an improved distribution in the parenchyma, particularly when atelectatic, and airways [7, 8] . Varela et al. illustrated the superiority of improved distribution of the retrograde perfusion in the bronchial tree over Table 4 : Univariate analysis of available donor, graft or recipient characteristics indicated that the incidence of post-transplant obstructive airway complication is significantly higher after bilateral lung transplantation (P = 0.011) Absence of graft obstructive airway complication (n = 129) Presence of graft obstructive airway complication (n = 40) the conventional pulmonary artery route, which might result in a lower incidence of bronchial anastomotic insufficiency [9] . Pulmonary gas exchange capacity and grade of intra-alveolar oedema following retrograde perfusion were significantly improved compared with the antegrade route [10, 12] . Strüber et al. reported beneficial effects on surfactant function and a reduced trend for post-transplant capillary leak and inflammatory response after retrograde lung preservation [11] . These results indicate a potential beneficial impact on early and late results following clinical lung transplantation.
The clinical technique and application of retrograde lung preservation was first described in 1993 for lung graft preservation in three consecutive heart-lung transplants. Lung graft function was adequate and patients were extubated within 24 h post-transplant [4] . The largest cohort to date reported on 21 lung grafts recovered using in situ retrograde preservation. Mostly, the recipients were extubated within 48 h and severe radiographic evidence of infiltrations were not seen. No stenoses were observed, only a bronchial dehiscence in 1 patient [13] . In lung recovery following severe pulmonary embolism, retrograde preservation enabled the use of these grafts for transplantation. All 3 patients were extubated within 8 days at the latest. No pulmonary complications occurred [14] . All three reports did not include a control group.
Reports on antegrade flush preservation in situ and a subsequent retrograde perfusion directly after recovery or prior to implantation describe a beneficial effect on gas exchange, airway pressures, chest radiograph scores according to infiltrations, pulmonary artery pressures or pulmonary vascular resistance. As a potential advantage, retrograde perfusion may lead to a better wash-out of clots or fats in donors [15] [16] [17] . Similarly, Oto et al. report on a retrograde exploratory flush prior to graft implantation and found unexpected emboli in 38% of their patients. Consecutively, patients with this evidence of emboli still had impaired graft function, radiograph scores and prolonged intrahospital treatment periods and, finally, decreased 1-year survival. Oto et al. hypothesized that emboli may reveal a potential mechanism for PGD [21] . In our cohort, we have noticed wash-out of emboli regularly.
In a preclinical model, Serrick et al. have seen a beneficial effect of a second rinse on functional parameters prior to implantation [22] . This effect may account for the observed improvement of graft function following a combined ante-and retrograde preservation in the above-mentioned studies. Ferraro et al. found no effect of a preimplantation flush on the severity of PGD in a retrospective analysis [3] .
However, in our study, we have not seen relevant trends for improved oxygenation indices in either cohort. There is evidence that systemic oxygenation by the lung graft remains the most sensitive parameter for adequate preservation in contrast to less sensitive criteria such as pulmonary artery pressure, peak airway pressure, lung compliance or post-transplant pulmonary oedema [23] .
Though an improved distribution of the preservation solution was seen preclinically and, thereby, an enhanced preservation of the bronchial tree may occur [6, 7] , this theoretical benefit did not materialize in our RP cohort. Anastomotic dehiscences remain a serious concern in lung transplant patients. There are several potential risk factors contributing to this complication. There is evidence that Euro-Collins solution compared with LPD, anastomotic technique, prolonged ventilation, CMV colonization, regional infections, ischaemic lesions and down-sizing of the graft may reflect some of those [5, 24, 25] . Evidence exists that corticosteroids may lead to an increased incidence of bronchial anastomotic complications.
Anastomotic or postanastomotic bronchial stenoses are frequently described. Early stenoses were described as attributable to ischaemia in the anastomotic region, localized infection or different bronchial anastomotic techniques [5, 24, 25] . In the RP cohort, the incidence of stenotic complications decreased, but not significantly. Only BLTx turned out to be a predictor in univariate analysis, and there was a trend toward a lower incidence following RP, but the number of patients in the RP cohort might be too small to potentially attribute the lower incidence to the perfusion technique.
In situ retrograde lung preservation is a clinically feasible technique for lung perfusion. We have not observed relevant clinical benefits of retrograde lung graft preservation in a basically comparable study group. Survival between groups was comparable. BOS-free survival mirrored a non-significant, but impaired trend in RP recipients. Bronchial anastomotic complications remain a serious complication with a variety of reported predictors. By means of the preservation route, the majority of published works report on a combination of antegrade and retrograde pulmonary preservation. In comparison with either antegrade or retrograde delivery, the combination of both may consecutively reveal an advantage. To elucidate some contradictory results, detailed future investigations are warranted.
Historically, grafts were preserved by means of autoperfusion with extracorporeal circulation, topical cooling or donor core cooling. In the 1980s, the standard lung preservation method was single pulmonary artery flush perfusion, using modified Euro-Collins solution at 4°C [1] . However, reperfusion injury remained a significant factor for morbidity and early mortality after lung transplant. Since the early years of lung preservation strategies, some advances have emerged in transplant teams, such as adding prostaglandin E2 to prevent counteract temperature and potassium-induced vasoconstriction. The use of low potassium dextran glucose solutions shows better overall lung function, superior early oxygenation, higher lung compliance, lower incidence of severe primary graft dysfunction and 30-day mortality [2] .
As Gohrbandt et al. point out, the route to administer the preservation solution may also have an impact on early lung graft performance [3] . Anterograde flush initiating the infusion through the pulmonary artery with pulmonary vein drainage was the traditional approach for many years [4] . This technique, however, presents a number of limitations. Flushing the pulmonary artery leaves the bronchial tissue to be preserved by topical cooling alone, raising the complication from the bronchial suture. Also, clots and fat or brain tissue emboli, especially in donors with major trauma and
